Optimising intraperitoneal gentamicin dosing in peritoneal dialysis patients with peritonitis (GIPD) study

Dwarakanathan Ranganathan, Julie M Varghese, Robert G Fassett, Jeffrey Lipman, Vincent D'Intini, Helen Healy, Jason A Roberts, Dwarakanathan Ranganathan, Julie M Varghese, Robert G Fassett, Jeffrey Lipman, Vincent D'Intini, Helen Healy, Jason A Roberts

Abstract

Background: Antibiotics are preferentially delivered via the peritoneal route to treat peritonitis, a major complication of peritoneal dialysis (PD), so that maximal concentrations are delivered at the site of infection. However, drugs administered intraperitoneally can be absorbed into the systemic circulation. Drugs excreted by the kidneys accumulate in PD patients, increasing the risk of toxicity. The aim of this study is to examine a model of gentamicin pharmacokinetics and to develop an intraperitoneal drug dosing regime that maximises bacterial killing and minimises toxicity.

Methods/design: This is an observational pharmacokinetic study of consecutive PD patients presenting to the Royal Brisbane and Women's Hospital with PD peritonitis and who meet the inclusion criteria. Participants will be allocated to either group 1, if anuric as defined by urine output less than 100 ml/day, or group 2: if non-anuric, as defined by urine output more than 100 ml/day. Recruitment will be limited to 15 participants in each group. Gentamicin dosing will be based on the present Royal Brisbane & Women's Hospital guidelines, which reflect the current International Society for Peritoneal Dialysis Peritonitis Treatment Recommendations. The primary endpoint is to describe the pharmacokinetics of gentamicin administered intraperitoneally in PD patients with peritonitis based on serial blood and dialysate drug levels.

Discussion: The study will develop improved dosing recommendations for intraperitoneally administered gentamicin in PD patients with peritonitis. This will guide clinicians and pharmacists in selecting the most appropriate dosing regime of intraperitoneal gentamicin to treat peritonitis.

Trial registration: ACTRN12609000446268.

References

    1. Brown F, Liu WJ, Kotsanas D, Korman TM, Atkins RC. A quarter of a century of adult peritoneal dialysis-related peritonitis at an Australian medical centre. Peritoneal Dialysis International. 2007;27(5):565–574.
    1. Davenport A. Peritonitis remains the major clinical complication of peritoneal dialysis: The London, UK, Peritonitis Audit 2002-2003. Peritoneal Dialysis International. 2009;29(3):297–302.
    1. Piraino B, Bailie GR, Bernardini J, Boeschoten E, Gupta A, Holmes C, Kuijper EJ, Li PK, Lye WC, Mujais S. Peritoneal dialysis-related infections recommendations: 2005 update. Peritoneal Dialysis International. 2005;25(2):107–131.
    1. Pancorbo S, Comty C. Pharmacokinetics of gentamicin in patients undergoing continuous ambulatory peritoneal dialysis. Antimicrobial Agents & Chemotherapy. 1981;19(4):605–607.
    1. Bunke CM, Aronoff GR, Brier ME, Sloan RS, Luft FC. Tobramycin kinetics during continuous ambulatory peritoneal dialysis. Clinical Pharmacology & Therapeutics. 1983;34(1):110–116.
    1. Keller E, Reetze P, Schollmeyer P. Drug therapy in patients undergoing continuous ambulatory peritoneal dialysis-clinical pharmacokinetic considerations. Clinical Pharmacokinetics. 1990;18(2):104–117. doi: 10.2165/00003088-199018020-00002.
    1. O'Brien MA, Mason NA. Systemic absorption of intraperitoneal antimicrobials in continuous ambulatory peritoneal dialysis. Clinical Pharmacy. 1992;11:246–254.
    1. Kent JR, Almond MK. A survey of CAPD peritonitis management and outcomes in North and South Thames NHS regions (U.K.): support for the ISPD guidelines. International Society for Peritoneal Dialysis. Peritoneal Dialysis International. 2000;20(3):301–305.
    1. Blunden M, Zeitlin D, Ashman N, Fan SL, Blunden M, Zeitlin D, Ashman N, Fan SLS. Single UK centre experience on the treatment of PD peritonitis--antibiotic levels and outcomes. Nephrology Dialysis Transplantation. 2007;22(6):1714–1719. doi: 10.1093/ndt/gfm079.
    1. Lye WC, Straaten JC van der, Leong SO, Sivaraman P, Tan SH, Tan CC, Lee EJ. Once-daily intraperitoneal gentamicin is effective therapy for gram-negative CAPD peritonitis. Peritoneal Dialysis International. 1999;19(4):357–360.
    1. Bailie GR, Haqqie SS, Eisele G, Gorman T, Low CL. Effectiveness of once-weekly vancomycin and once-daily gentamicin, intraperitoneally, for CAPD peritonitis.[see comment] Peritoneal Dialysis International. 1995;15(6):269–271.
    1. Weber J, Staerz E, Mettang T, Machleidt C, Kuhlmann U. Treatment of peritonitis in continuous ambulatory peritoneal dialysis (CAPD) with intraperitoneal cefazolin and gentamicin. Peritoneal Dialysis International. 1989;9(3):191–195.
    1. Lye WC, Wong PL, Straaten JC van der, Leong SO, Lee EJ. A prospective randomized comparison of single versus multidose gentamicin in the treatment of CAPD peritonitis. Advances in Peritoneal Dialysis. 1995;11:179–181.
    1. de Paepe M, Lameire N, Belpaire F, Bogaert M. Peritoneal pharmacokinetics of gentamicin in man. Clinical Nephrology. 1983;19(3):107–109.
    1. Tosukhowong T, Eiam-Ong S, Thamutok K, Wittayalertpanya S, Na Ayudhya DP. Pharmacokinetics of intraperitoneal cefazolin and gentamicin in empiric therapy of peritonitis in continuous ambulatory peritoneal dialysis patients. Peritoneal Dialysis International. 2001;21(6):587–594.
    1. Low CL, Bailie GR, Evans A, Eisele G, Venezia RA. Pharmacokinetics of once-daily IP gentamicin in CAPD patients. Peritoneal Dialysis International. 1996;16(4):379–384.
    1. Mars RL, Moles K, Pope K, Hargrove P. Use of bolus intraperitoneal aminoglycosides for treating peritonitis in end-stage renal disease patients receiving continuous ambulatory peritoneal dialysis and continuous cycling peritoneal dialysis. Advances in Peritoneal Dialysis. 2000;16:280–284.
    1. Manley HJ, Bailie GR, Asher RD, Eisele G, Frye RF. Pharmacokinetics of intermittent intraperitoneal cefazolin in continuous ambulatory peritoneal dialysis patients. Peritoneal Dialysis International. 1999;19(1):65–70.
    1. Shemin D, Maaz D, St Pierre D, Kahn SI, Chazan JA. Effect of aminoglycoside use on residual renal function in peritoneal dialysis patients. American Journal of Kidney Diseases. 1999;34(1):14–20. doi: 10.1016/S0272-6386(99)70102-2.
    1. Baker RJ, Senior H, Clemenger M, Brown EA, Baker RJ, Senior H, Clemenger M, Brown EA. Empirical aminoglycosides for peritonitis do not affect residual renal function. American Journal of Kidney Diseases. 2003;41(3):670–675. doi: 10.1053/ajkd.2003.50129.
    1. Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. Journal of Infectious Diseases. 1987;155:93–99.
    1. Vogelman BS, Craig WA. Postantibiotic effects. Journal of Antimicrobial Chemotherapy. 1985;15:37–46.
    1. Begg EJ, Barclay ML. Aminoglycosides-50 years on. British Journal of Clinical Pharmacology. 1995;39(6):597–603.
    1. Powers JD. Statistical considerations in pharmacokinetic study design. Clinical Pharmacokinetics. 1993;24(5):380–387. doi: 10.2165/00003088-199324050-00003.
    1. Bradley JS, Dudley MN, Drusano GL. Predicting efficacy of antiinfectives with pharmacodynamics and Monte Carlo simulation. Pediatric Infectious Disease Journal. 2003;22(11):982–992. doi: 10.1097/01.inf.0000094940.81959.14.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj